Newsroom | 95751 results

NEW YORK--(BUSINESS WIRE)--Napoli Shkolnik has filed a motion for spoliation sanctions, alleging that McKinsey & Company destroyed, concealed, or failed to preserve evidence in the ongoing opioid litigation brought by 44 New York municipalities. Napoli Shkolnik partner Paul J. Napoli is co-lead counsel in the New York Opioid Cost Recovery Litigation. "McKinsey has spent years trying to make this litigation go away, through settlements, through silence, and, as this motion alleges, through t...

CHICAGO--(BUSINESS WIRE)--Newly released rankings from U.S. News & World Report underscore the significant role osteopathic medical schools play in preparing physicians to serve in high-need areas across the country. The latest data show that colleges of osteopathic medicine (COMs) continue to distinguish themselves in graduating Doctor(s) of Osteopathic Medicine (DOs) who enter primary care and practice in rural and medically underserved communities. According to the rankings: Osteopathic...

CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a high-stability AAV vector designed to address ITR instability, a common challenge in gene therapy development. The manuscript describing the technology is now available on bioRxiv. Adeno-associated virus (AAV) remains one of the most widely used gene delivery platforms for therapeutic development. However, inconsistencies in manufacturing and variable thera...

EATONTOWN, N.J.--(BUSINESS WIRE)--Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in CNS drug and device development, today announced it has successfully completed an inspection by the U.S. Food and Drug Administration (FDA) with no observations. This outcome underscores Clinilabs continued commitment to the highest standards of regulatory compliance, operational excellence, and patient safety across its clinical research programs. “Each FDA...

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced the appointment of Viet Nguyen as Chief Operating Officer and Arlene Wolny as Senior Vice President of Regulatory Affairs. Both leaders will be based in Piscataway, New Jersey. Viet Nguyen has over two decades of leadership experience, with deep expertise in building high-performing teams, scaling complex operations, and driving commercial readiness across mu...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmuVia Inc., a biotechnology company developing first-in-class therapies for solid tumors, today announced that it has selected Quantori, a leading provider of digital transformation services and technology for the life sciences and healthcare industries, as a strategic technology partner. ImmuVia will deploy Quantori’s Q-Scientist platform to streamline computational workflows across its preclinical programs, with the goal of compressing development timeline...

SANTA CLARA, Calif.--(BUSINESS WIRE)--ValGenesis to debut the next generation of VAL™ (ValGenesis AI) at INTERPHEX 2026. Visit booth 3552 for demos and pilot program information....

ROCKVILLE, Md.--(BUSINESS WIRE)--Linden Lake Labs (“L3”), an early-stage life sciences platform committed to advancing innovative therapies, today announced that its portfolio company, CrossBridge Bio, has entered into a definitive agreement to be acquired by Eli Lilly and Company. Linden Lake Labs participated in CrossBridge Bio’s seed financing round in November 2024, supporting the early development of its differentiated dual-payload antibody-drug conjugate (ADC) platform. “This milestone re...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Antiva reports Phase 1b/2 data showing ABI-2280 clears high-risk HPV with strong efficacy, durability, and safety vs placebo....

CAMBRIDGE, Mass. & MALVERN, Pa.--(BUSINESS WIRE)--Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor through clinical development for patients with the hardest-to-treat forms of advanced breast cancer, and Obsidian Therapeutics, Inc. (“Obsidian”), a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte, (“TIL”), c...